MikkelDLund
@mdlund.bsky.social
Reposted by MikkelDLund
Can you dose escalate locally advanced NSCLC to 88+ Gy without excess toxicity?
Yes! If you use heterogeneous dose escalation & careful QA.
6-month toxicity data from the Scandinavian phase III dose escalation NARLAL2 trial now online in JCO:
ascopubs.org/doi/abs/10.1...
#radonc
Yes! If you use heterogeneous dose escalation & careful QA.
6-month toxicity data from the Scandinavian phase III dose escalation NARLAL2 trial now online in JCO:
ascopubs.org/doi/abs/10.1...
#radonc
Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non–Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial
PURPOSERadiation dose escalation for locally advanced non–small cell lung cancer (LA-NSCLC)
has been challenged by toxicity concerns. The Scandinavian phase III multicenter dose-escalation
trial NARLA...
ascopubs.org
April 23, 2025 at 1:30 AM
Can you dose escalate locally advanced NSCLC to 88+ Gy without excess toxicity?
Yes! If you use heterogeneous dose escalation & careful QA.
6-month toxicity data from the Scandinavian phase III dose escalation NARLAL2 trial now online in JCO:
ascopubs.org/doi/abs/10.1...
#radonc
Yes! If you use heterogeneous dose escalation & careful QA.
6-month toxicity data from the Scandinavian phase III dose escalation NARLAL2 trial now online in JCO:
ascopubs.org/doi/abs/10.1...
#radonc